Renati Innovation S.A.P.I. DE C.V.

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer4 trials
• Lung cancer1 trial

Phase

• Phase 33 trials
• Phase 22 trials

Status

• Active, not recruiting2 trials
• Completed2 trials
• Recruiting1 trial

Lead sponsor

• Hoffmann-La Roche3 trials
• Carrick Therapeutics Limited1 trial
• Summit Therapeutics1 trial

Running trials

• Recruiting

  To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

  NCT07368998· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Summit Therapeutics· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer1 recruiting

Closed trials

• Completed

  A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

  NCT05963984· Phase 2· Carrick Therapeutics Limited· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Hoffmann-La Roche· Source